Analysts Set Expectations for CVS Health FY2025 Earnings

CVS Health Co. (NYSE:CVS - Free Report) - Equities research analysts at Cantor Fitzgerald boosted their FY2025 earnings per share estimates for CVS Health in a research report issued to clients and investors on Sunday, May 4th. Cantor Fitzgerald analyst S. James now expects that the pharmacy operator will post earnings of $6.12 per share for the year, up from their prior forecast of $5.86. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for CVS Health's current full-year earnings is $5.89 per share.

CVS has been the subject of a number of other reports. Wolfe Research lifted their price objective on CVS Health from 67.00 to 70.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. JPMorgan Chase & Co. lifted their price target on shares of CVS Health from $80.00 to $81.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 18th. Morgan Stanley restated an "overweight" rating on shares of CVS Health in a report on Tuesday, April 15th. Barclays lifted their target price on shares of CVS Health from $73.00 to $82.00 and gave the stock an "overweight" rating in a report on Friday, May 2nd. Finally, Edward Jones upgraded CVS Health from a "hold" rating to a "buy" rating in a research report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $74.81.

CVS Health Trading Down 1.3 %

CVS traded down $0.87 during mid-day trading on Tuesday, reaching $66.98. The stock had a trading volume of 6,356,260 shares, compared to its average volume of 11,403,578. The stock has a market capitalization of $84.45 billion, a P/E ratio of 18.30, a P/E/G ratio of 0.98 and a beta of 0.60. CVS Health has a 52 week low of $43.56 and a 52 week high of $72.51. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The firm's fifty day simple moving average is $66.96 and its two-hundred day simple moving average is $59.03.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating the consensus estimate of $1.62 by $0.63. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The business had revenue of $94.59 billion for the quarter, compared to analysts' expectations of $93.07 billion. During the same period in the prior year, the firm earned $1.31 earnings per share. CVS Health's revenue was up 7.0% compared to the same quarter last year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were paid a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 3.97%. The ex-dividend date of this dividend was Tuesday, April 22nd. CVS Health's dividend payout ratio is 63.48%.

Insider Transactions at CVS Health

In related news, Director Michael F. Mahoney bought 30,000 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were acquired at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the acquisition, the director now owns 39,356 shares of the company's stock, valued at approximately $2,625,045.20. The trade was a 320.65 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP James David Clark sold 7,513 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares of the company's stock, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their position. The disclosure for this sale can be found here. 1.22% of the stock is owned by insiders.

Institutional Trading of CVS Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in CVS. Principal Financial Group Inc. boosted its stake in shares of CVS Health by 4.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator's stock worth $90,200,000 after acquiring an additional 66,244 shares during the period. InvesTrust acquired a new stake in shares of CVS Health during the 4th quarter worth about $1,823,000. Watts Gwilliam & Co. LLC raised its holdings in CVS Health by 9.8% in the 4th quarter. Watts Gwilliam & Co. LLC now owns 7,302 shares of the pharmacy operator's stock valued at $334,000 after acquiring an additional 650 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in CVS Health by 1.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 173,643 shares of the pharmacy operator's stock worth $7,795,000 after acquiring an additional 2,256 shares during the last quarter. Finally, Ridgewood Investments LLC increased its stake in shares of CVS Health by 255.7% during the fourth quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock worth $28,000 after purchasing an additional 450 shares during the period. 80.66% of the stock is owned by institutional investors.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.